Heparin-Binding Protein and Heparins

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-01

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heparin-Binding protein is a protein from primary and secretory granluae of white blood cells. It is released when white blood cells become activated and has been advocated as a biomarker for sepsis. The aim of this study is to find out if Heparins in clinical doses can change the level of Heparin-binding protein in plasma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Heparin Binding Protein in Early Sepsis Diagnosis

NCT03295825

Sepsis Infection

COMPLETED NA

Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis

NCT03113721

Sepsis Septic Shock Sepsis With Acute Organ Dysfunction

UNKNOWN

Evaluation of the Heparin Binding Protein Levels in Sepsis

NCT02533011

Sepsis Infection Septic Shock

COMPLETED

Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?

NCT03682003

Severe Sepsis or Septic Shock

UNKNOWN

IMproved PREdiction of Severe Sepsis in the Emergency Department

NCT01392508

Systemic Inflammatory Response Syndrome (SIRS) Sepsis Severe Sepsis +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Blood samples are taken from patients before and after Heparins in clinical doses. The effects of heparins on Heparin-binding protein concentration in plasma is measured. This is a small observational study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Disease, Peripheral Thromboprophylaxis Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vascular surgery group

Patients which are given unfractionated heparin during their vascular surgery.

Blood samples for Heparin-binding protein measurement

Intervention Type DIAGNOSTIC_TEST

Blood samples before and after given heparin

Thromboprophylaxis group

Patients which are given low molecular heparins as a thrombosprofylax after major surgery

Blood samples for Heparin-binding protein measurement

Intervention Type DIAGNOSTIC_TEST

Blood samples before and after given heparin

Cardiothoracic surgery

Patients which are given high dose unfractionated heparin during their open heart surgey

Blood samples for Heparin-binding protein measurement

Intervention Type DIAGNOSTIC_TEST

Blood samples before and after given heparin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples for Heparin-binding protein measurement

Blood samples before and after given heparin

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Planned endovascular treatment of aortic aneurysm or peripheral vascular surgery where unfractionated heparin in \>3000 units are given perioperatively
* Planned subcutaneous low molecular weight heparin as a thromboprophylactic treatment after major surgery or on Intensive Care treated patients.
* Planned open heart surgery with cardiopulmonary bypass.